COVID-19 vaccines: safety profile after one year of follow-up
DOI:
https://doi.org/10.30827/ars.v65i1.29180Keywords:
COVID-19, pharmacovigilance, vaccines, safetyAbstract
Introduction: After declaring the global pandemic due to the coronavirus COVID-19, measures were established to combat it, highlighting the existence of COVID-19 vaccines: two messenger RNA [mRNA] and two non-replicating viral vector [VVNR].
Our objective was to contribute to expanding the safety profile of these vaccines through the detection and notification of adverse reactions (ARs) in a health area with 174,398 health cards during the year 2021.
Method: Retrospective descriptive observational study carried out in a second level hospital. The sources of detection of the ADRs were: Coding System of the Center at the Discharge of the Admitted Patient [SIAC] and spontaneous notification. The data used were extracted from the electronic medical record and collected in a Microsoft Excell document.
Results: Of the 654 ARs detected, 36 belonged to COVID-19 vaccines, 72 % being detected by spontaneous notification and 91.67 % being serious. They occurred in 29 patients (median age: 61 years; 51.72 % women), two of them with previous COVID-19 infection. 50 % of the ARs occurred after the second dose. They highlighted: deep vein thrombosis (DVT), pulmonary thromboembolism (PTE) and myopericarditis with mRNA vaccines; and vasculitis and myocarditis in VVNR.
Conclusions: Although the available bibliography indicates that the frequency of serious ARs with these vaccines is usually rare, their follow-up is important. The high percentage of ADRs detected by spontaneous notification reflects the involvement of healthcare professionals to expanding the safety profile.
Downloads
References
Docea AO, Tsatsakis A, Albulescu D et al. A new threat from an old enemy: Re-emergence of coronavirus (Review). Int J Mol Med. 2020; 45: 1631-1643. Doi:10.3892/ijmm.2020.4555
Fathizadeh H, Maroufi P, Momen‑Heravi M et al. Protection and desinfection policies against SARS-CoV-2 (COVID-19). Infez Med. 2020; 28: 185-191.
Comirnaty, INN-Tozinameran, tozinameran/ritozinameran. [Ficha Técnica; Online]. Disponible en: https://cima.aemps.es/cima/pdfs/ft/1201528001/FT_1201528001.pdf [Consultada a 13 Noviembre 2022].
Vaxzevria® COVID-19 Vaccine (ChAdOx1-S [recombinant]). [Ficha Técnica; Online]. Disponible en: https://cima.aemps.es/cima/pdfs/ft/1211529001/FT_1211529001.pdf [Consultada a 13 Noviembre 2022].
JCOVDEN®, INN-Ad.26.COV2-S recombinant. [Ficha Técnica; Online]. Disponible en: https://cima.aemps.es/cima/pdfs/ft/1201525001/FT_1201525001.pdf [Consultada a 13 Noviembre 2022].
Spikevax, INN-elasomeran/imelasomeran/davesomeran. [Ficha Técnica; Online]. Disponible en: https://cima.aemps.es/cima/pdfs/ft/1201507001/FT_1201507001.pdf [Consultada a 13 Noviembre 2022].
Solsona EM. La farmacia hospitalaria: una gran aliada en la contribución al éxito de la campaña de vacunación frente a la COVID-19. OFIL ILAPHAR. 2021; 31(2):125-126.
WHO Coronavirus (COVID-19) Dashboard [Online]. Disponible en: https://covid19.who.int/ [Consultada a 13 Noviembre 2022].
Informes periódicos de farmacovigilancia de vacunas COVID-19 [Online] 2022. Disponible en: https://www.aemps.gob.es/la-aemps/ultima-informacion-de-la-aemps-acerca-del-covid%e2%80%9119/vacunas-contra-la-covid%e2%80%9119/farmacovigilancia-de-vacunas/informes-periodicos-de-farmacovigilancia-de-vacunas-covid-19/ [Consultada a 15 Diciembre 2022].
Graña C, Ghosn L, Evrenoglou T et al. Efficacy and safety of COVID-19 vaccines (Review). Cochrane Database of Systematic Reviews. 2022; 12. Doi: 10.1002/14651858.CD015477.
Seguridad de las vacunas contra el COVID-19. CDC. [Online]. Disponible en:https://espanol.cdc.gov/coronavirus/2019-ncov/vaccines/safety/safety-of-vaccines.html [Consultada a 17 Diciembre 2022].
Información para las notificaciones de sospechas de reacciones adversas a medicamentos por parte de profesionales sanitarios [Online]. Disponible en: https://www.aemps.gob.es/medicamentos-de-uso-humano/farmacovigilancia-de-medicamentos-de-uso-humano/notificacion-de-sospechas-de-reacciones-adversas-a-medicamentos-ram-de-uso-humano/notificasospechas-ram-profsanitarios/ [Consultada a 8 Abril 2023].
Gómez Marco JJ, Álvarez Pasquín MJ, Martín Martín S. Efectividad y seguridad de las vacunas para el SARS-CoV-2 actualmente disponibles. FMC. 2021; 28(8):442-51.
Esparza Olcina MJ, Fraile Astorga G, Juanes de Toledo B et al. Eficacia y seguridad de las vacunas contra el SARS-CoV-2. Rev Pediatr Aten Primaria. 2022; 24:e171-e182.
Actualización sobre el riesgo de miocarditis y pericarditis con las vacunas de ARNm frente a la COVID-19 [Online]. Disponible en:https://www.aemps.gob.es/informa/actualizacion-sobre-el-riesgo-de-miocarditis-y-pericarditis-con-las-vacunas-de-arnm-frente-a-la-covid-19/ [Consultada a 14 Diciembre 2022].
ZOE COVID Symptom Study. Vaccine after effects more common in those who already had COVID-19 [Online]. 2021. Disponible en: https://covid.joinzoe.com/post/vaccine-after-effects-more-common-in-those-who-already-had-covid. [Consultada a 1 Enero 2023]
Sharif N, Alzahrani KJ, Ahmed SN and Dey SK. Efficacy, Immunogenicity and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis. Front Immunol. 2021; 12: 714170. Doi: 10.3389/fimmu.2021.714170.
Kantor IN, Lüthy IA, Ritacco V. Las variantes de SARS-CoV-2 y la llamada Resistencia a las vacunas. Medicina (Buenos Aires). 2021; 81:421- 426.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Alba María Fernández Varela, Mónica Granero López, Alejandro Rodríguez Rodríguez, Isaura Rodríguez Penín
![Creative Commons License](http://i.creativecommons.org/l/by-nc-sa/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The articles, which are published in this journal, are subject to the following terms in relation to the rights of patrimonial or exploitation:
- The authors will keep their copyright and guarantee to the journal the right of first publication of their work, which will be distributed with a Creative Commons BY-NC-SA 4.0 license that allows third parties to reuse the work whenever its author, quote the original source and do not make commercial use of it.
b. The authors may adopt other non-exclusive licensing agreements for the distribution of the published version of the work (e.g., deposit it in an institutional telematic file or publish it in a monographic volume) provided that the original source of its publication is indicated.
c. Authors are allowed and advised to disseminate their work through the Internet (e.g. in institutional repositories or on their website) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).